OR

Browse By

The development of tyrosine kinase inhibitors for the treatment of inflammation and malignant disease. (2004–2007)

Abstract:
Through the combination of expertise from the Industry partner and the Hume group this project aims to develop specific inhibitors of the CSF-1 receptor protein tyrosine kinase in order to demonstrate their efficacy as modulators of CSF-1 dependent macrophage and tumour cell function in vitro. The expected outcome will be a lead set of targets which can be further assessed for therapeutic potential in clinical trials.
Grant type:
ARC Linkage Projects
Researchers:

  • Professor David Hume

    Professor
    Mater Research Institute-UQ
    Faculty of Medicine

  • Professor Matt Sweet

    NHMRC Leadership Fellow - GL
    Institute for Molecular Bioscience
    Affiliate NHMRC Leadership Fellow
    School of Chemistry and Molecular Biosciences
    Faculty of Science
Funded by:
Australian Research Council